This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Consumer Health Information Corporation Warns Poor Patient Adherence In Clinical Drug Trials May Be Putting The Public At Risk

MCLEAN, Va., Feb. 12, 2013 /PRNewswire/ -- Every person taking a prescription drug should be able to trust that the recommended dose is safe.  This may not always be the case according to  Dr. Dorothy L. Smith, President and CEO of Consumer Health Information Corporation. In the last ten years, many patients have developed unexpected toxicities from prescription drugs that have been on the market for 5-10 years.  FDA has responded by cutting the doses of several drugs in half and withdrawing others. During this same time period, patient adherence in the general population has been increasing due to media attention and improved patient education by health professionals.

"Why have there been so many unexpected toxicities in the last 10 years after these drugs have been approved? Why are approved doses later being cut in half?  Could there be a link to patient adherence?" To try to answer these questions, Dr. Smith reviewed the last 20 years of the patient adherence research in clinical trials.  The findings were shocking:

  • Between 1997-1999, patient adherence was not monitored in 53% of clinical trials.  Many of these drugs are still on the market.
  • Up to 30% of study patients do not take the full dose of the study drug. 
  • Study patients cannot understand 35% - 94% of Informed Consent documents.
  • At least 50% of study patients do not tell the study team they missed doses.
  • Many study patients do not realize that missing doses could endanger the lives of millions of people after the drug is approved.
  • Poor patient adherence that is undetected in clinical trials may result in a dose that is inaccurate and too high.

Unexpected adverse drug reactions and toxicity could occur when patients in the general population are more adherent than those in the clinical trial.  Dr. Smith urged clinical trial investigators to:

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs